Xintela AB (Sweden) Insiders
| XINT Stock | SEK 0.33 0.01 3.13% |
Xintela AB employs about 16 people. The company is managed by 4 executives with a total tenure of roughly 18 years, averaging almost 4.0 years of service per executive, having 4.0 employees per reported executive. Breaking down Xintela AB's management performance can provide insight into the firm performance.
| BSc JD Insider Ex Chairman |
| Thomas Areschoug Executive Business Development Manager |
Xintela |
Xintela AB Management Team Effectiveness
The company has return on total asset (ROA) of (1.1374) % which means that it has lost $1.1374 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (4.6888) %, meaning that it generated substantial loss on money invested by shareholders. Xintela AB's management efficiency ratios could be used to measure how well Xintela AB manages its routine affairs as well as how well it operates its assets and liabilities.Xintela AB Workforce Comparison
Xintela AB is rated first in number of employees category among its peers. The total workforce of Biotechnology industry is at this time estimated at about 11,826. Xintela AB adds roughly 16.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Xintela AB Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Xintela AB Price Series Summation is a cross summation of Xintela AB price series and its benchmark/peer.
Xintela AB Notable Stakeholders
A Xintela AB stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Xintela AB often face trade-offs trying to please all of them. Xintela AB's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Xintela AB's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Gunnar Telhammar | CFO Director | Profile | |
| BSc JD | Ex Chairman | Profile | |
| Thomas Areschoug | Business Development Manager | Profile | |
| Per Norlen | Chief Officer | Profile |
About Xintela AB Management Performance
The success or failure of an entity such as Xintela AB often depends on how effective the management is. Xintela AB management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Xintela management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Xintela management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Xintela AB , a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company was founded in 2009 and is based in Lund, Sweden. Xintela AB operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 13 people.
Please note, the imprecision that can be found in Xintela AB's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Xintela AB. Check Xintela AB's Beneish M Score to see the likelihood of Xintela AB's management manipulating its earnings.
Xintela AB Workforce Analysis
Traditionally, organizations such as Xintela AB use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Xintela AB within its industry.Xintela AB Manpower Efficiency
Return on Xintela AB Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.6M | |
| Net Loss Per Executive | 14.6M |
Additional Tools for Xintela Stock Analysis
When running Xintela AB's price analysis, check to measure Xintela AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xintela AB is operating at the current time. Most of Xintela AB's value examination focuses on studying past and present price action to predict the probability of Xintela AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xintela AB's price. Additionally, you may evaluate how the addition of Xintela AB to your portfolios can decrease your overall portfolio volatility.